Telix制药公司在2025年获得804M美元的收入,美国Gozellix的CMS后销售和高级关键癌症药物试验的推动下,2025年获得了804M美元的收入。 Telix Pharmaceuticals hit $804M in 2025 revenue, boosted by U.S. Gozellix sales post-CMS approval, and advanced key cancer drug trials.

Telix制药公司报告说,2025年全年收入为8.04亿美元,达到了更新的指导意见,Q4收入逐年增加46%,其驱动因素是美国在CMS偿还后推出Gozellix。 Telix Pharmaceuticals reported full-year 2025 revenue of $804 million, meeting upgraded guidance, with Q4 revenue up 46% year-over-year, driven by the U.S. launch of Gozellix following CMS reimbursement. 该公司推进了多种临床试验,包括为TLX591-Tx的TLXACT第3阶段研究和TLX090-Tx的SOLACE第1阶段美国第一名病人进行的PROSTACT第3阶段研究的全球入学情况。 The company advanced multiple clinical trials, including global enrollment in the ProstACT Phase 3 study for TLX591-Tx and first U.S. patients in the SOLACE Phase 1 trial for TLX090-Tx. Telix还宣布与Varian合作,探讨将放射药剂与辐射疗法相结合的问题,并在澳大利亚获得批准,开始ALPHIX试验。 Telix also announced a collaboration with Varian to explore combining radiopharmaceuticals with radiation therapy and received approval in Australia to begin the ALPHIX trial. TLX101-Tx、TLX102-Tx和TLX250-Tx的附加试验正在进行中或准备激活。 Additional trials for TLX101-Tx, TLX102-Tx, and TLX250-Tx are underway or preparing for activation. 尽管TLX250-CDx的监管延迟,以及最近的股票下跌,分析师将Telix升级为超强,理由是强的基本面和长期管道潜力. Despite regulatory delays for TLX250-CDx and a recent stock decline, analysts upgraded Telix to Outperform, citing strong fundamentals and long-term pipeline potential.